Table 3.

Association of iron use with retinal or subretinal hemorrhage in the study eye of CATT participants at baseline among those without past history or on-going anemia (n=1021)

			Unadjusted analysis		Adjusted analysis†
Iron use at baseline	n	Hemorrhage (%)	OR (95% CI)	P-value	OR (95% CI)	P-value
All subjects without anemia at baseline (n=1021)
Iron use				0.15		0.09
No	894	532 (59.5%)	1.00		1.00
Yes	127	84 (66.1%)	1.33 (0.90 – 1.97)		1.43 (0.95 – 2.14)
Iron dose				0.12*		0.07*
No iron use	894	532 (59.5%)	1.00		1.00
<18 mg	35	22 (62.9%)	1.15 (0.57 – 2.32)	0.69	1.16 (0.57 – 2.39)	0.68
18–36 mg	70	49 (70.0%)	1.59 (0.94 – 2.69)	0.09	1.89 (1.09 – 3.27)	0.02
>36 mg	13	7 (53.8%)	0.79 (0.27 – 2.38)	0.68	0.65 (0.21 – 2.00)	0.45
Without hypertension at baseline (n=323)
Iron use				0.61		0.81
No	287	172 (59.9%)	1.00		1.00
Yes	36	20 (55.6%)	0.83 (0.42 – 1.68)		0.86 (0.52 – 1.43)
Iron dose				0.76*		0.91*
No iron use	287	172 (59.9%)	1.00		1.00
<18 mg	10	6 (60.0%)	1.00 (0.28 – 3.63)	1.00	1.15 (0.29 – 4.60)	0.85
18–36 mg	18	12 (66.7%)	1.34 (0.49 – 3.66)	0.57	1.50 (0.52 – 4.38)	0.46
>36 mg	5	1 (20.0%)	0.17 (0.02 – 1.52)	0.11	0.16 (0.02 – 1.56)	0.12
With hypertension at baseline (n=698)
Iron use				0.04		0.02
No	607	360 (59.3%)	1.00		1.00
Yes	91	64 (70.3%)	1.63 (1.01 – 2.62)		1.85 (1.12 – 3.05)
Iron dose				0.06*		0.02*
Not use iron	607	360 (59.3%)	1.00		1.00
<18 mg	25	16 (64.0%)	1.22 (0.53 – 2.80)	0.64	1.36 (0.58 – 3.22)	0.48
18–36 mg	52	37 (71.2%)	1.69 (0.91 – 3.15)	0.10	2.05 (1.07 – 3.92)	0.03
>36 mg	8	6 (75.0%)	2.06 (0.41 – 10.3)	0.38	1.86 (0.36 – 9.73)	0.46

OR= odds ratio; CI= confidence interval.

^*From test of linear trend. No dose information is available for 9 patients (3 without hypertension, 6 with hypertension), they were excluded from the analysis of dose association.

^†Adjusted by age, gender, smoking status, dietary supplement use, hypertension, diabetes, CVD history, use of antiplatelet or anticoagulant, and CNV in fellow eye.